See more : Shanghai Carthane Co.,Ltd. (603037.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Codiak BioSciences, Inc. (CDAK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Codiak BioSciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Morito Co., Ltd. (9837.T) Income Statement Analysis – Financial Results
- Bread Financial Holdings, Inc. (ADS) Income Statement Analysis – Financial Results
- Digital Magics S.p.A. (DM.MI) Income Statement Analysis – Financial Results
- Koszalinskie Przedsiebiorstwo Przemyslu Drzewnego Spólka Akcyjna (KPD.WA) Income Statement Analysis – Financial Results
- T-Mobile US, Inc. (TM5.DE) Income Statement Analysis – Financial Results
Codiak BioSciences, Inc. (CDAK)
About Codiak BioSciences, Inc.
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 22.94M | 2.92M | 388.00K | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 22.94M | 2.92M | 388.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 64.86M | 73.98M | 59.50M | 36.54M |
| General & Administrative | 27.63M | 19.85M | 21.04M | 9.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.63M | 19.85M | 21.04M | 9.90M |
| Other Expenses | 0.00 | 906.00K | 992.00K | 0.00 |
| Operating Expenses | 92.48M | 93.83M | 80.54M | 46.44M |
| Cost & Expenses | 92.48M | 93.83M | 80.54M | 46.44M |
| Interest Income | 22.00K | 253.00K | 1.50M | 1.36M |
| Interest Expense | 2.70M | 1.91M | 300.00K | 0.00 |
| Depreciation & Amortization | 6.42M | 1.16M | 5.26M | 1.73M |
| EBITDA | -61.33M | -89.76M | -74.89M | -42.82M |
| EBITDA Ratio | -267.39% | -3,079.21% | -19,301.03% | 0.00% |
| Operating Income | -69.55M | -90.92M | -80.15M | -46.44M |
| Operating Income Ratio | -303.24% | -3,118.97% | -20,657.73% | 0.00% |
| Total Other Income/Expenses | 32.39M | -747.00K | 2.19M | 1.90M |
| Income Before Tax | -37.16M | -91.67M | -77.96M | -44.54M |
| Income Before Tax Ratio | -162.01% | -3,144.60% | -20,092.78% | 0.00% |
| Income Tax Expense | 4.48M | -2.73M | 1.29M | 1.90M |
| Net Income | -41.63M | -88.93M | -79.25M | -44.54M |
| Net Income Ratio | -181.53% | -3,050.81% | -20,425.77% | 0.00% |
| EPS | -1.91 | -14.04 | -6.03 | -3.40 |
| EPS Diluted | -1.91 | -14.04 | -6.03 | -3.40 |
| Weighted Avg Shares Out | 21.79M | 6.33M | 13.13M | 13.11M |
| Weighted Avg Shares Out (Dil) | 21.79M | 6.33M | 13.13M | 13.11M |
Codiak BioSciences, Inc. (CDAK) Stock Jumps 18.2%: Will It Continue to Soar?
Codiak BioSciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
Codiak BioSciences (CDAK) Stock: Why The Price Jumped Today
Codiak BioSciences to Present at the 4th Annual Evercore ISI HealthCONx Conference
Codiak BioSciences' Exosome Candidate Shows Tumor Shrinkage In Early Study
Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Misses Revenue Estimates
Codiak to Present Preclinical Data Demonstrating New Potential Therapeutic Applications of Engineered Exosomes at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Codiak BioSciences Appoints Lini Pandite, MBChB, MBA to Board of Directors
Codiak BioSciences to Present at the Virtual William Blair Biotech Focus Conference 2021
Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles
Source: https://incomestatements.info
Category: Stock Reports